Some novel therapies, such as antiepidermal growth factor receptor (EGFR) or programmed cell death 1 (PD-1) antibodies, can be clinically applied; however, patients with late-stage oral cancer have limited treatment options. This evidence concerns the gene PDCD1 and lip and oral cavity carcinoma.